14-6-1　ⓔ文献

  1. Olivarius Nde F, Andreasen AH, et al: Epidemiology of renal involvement in newly–diagnosed middle–aged and elderly diabetic patients. Cross–sectional data from the population–based study "Diabetes Care in General Practice", Denmark. Diabetologia, 1993; 36: 1007–1016.

  2. Stevens PE, Levin A: Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group M: Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med, 2013; 158: 825–830.

  3. Afkarian M, Zelnick LR, et al: Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988–2014. JAMA, 2016; 316: 602–610.

  4. Kume S, Araki SI, et al: Secular changes in clinical manifestations of kidney disease among Japanese adults with type 2 diabetes from 1996 to 2014. J Diabetes Investig, 2019; 10: 1032–1040.

  5. Tervaert TW, Mooyaart AL, et al: Pathologic classification of diabetic nephropathy. J Am Soc Nephrol, 2010; 21: 556–563.

  6. Cea Soriano L, Johansson S, et al: Cardiovascular events and all–cause mortality in a cohort of 57,946 patients with type 2 diabetes: associations with renal function and cardiovascular risk factors. Cardiovasc Diabetol, 2015; 14: 38.

  7. Bentata Y, Karimi I, et al: Albuminuria in type 2 diabetes mellitus: from remission to progression. Ren Fail, 2016; 38: 481–483.

  8. Yokoyama H, Araki S, et al: Association between remission of macroalbuminuria and preservation of renal function in patients with type 2 diabetes with overt proteinuria. Diabetes Care, 2013; 36: 3227–3233.

  9. Coresh J, Turin TC, et al: Decline in estimated glomerular filtration rate and subsequent risk of end–stage renal disease and mortality. JAMA, 2014; 311: 2518–2531.

  10. Rossing K, Christensen PK, et al: Progression of nephropathy in type 2 diabetic patients. Kidney Int, 2004; 66: 1596–1605.

  11. Jardine MJ, Mahaffey KW, et al: Canagliflozin and Renal Outcomes in Diabetic Nephropathy. Reply. N Engl J Med, 2019; 381: 1089–1090.

  12. Adler AI, Stratton IM, et al: Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ, 2000; 321: 412–419.

  13. Brenner BM, Cooper ME, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med, 2001; 345: 861–869.

  14. Investigators O, Yusuf S, et al: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med, 2008; 358: 1547–1559.

  15. Perkovic V, Jardine MJ, et al: Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med, 2019; 380: 2295–2306.